(Reuters) – Regeneron Pharmaceuticals Inc said on Wednesday that its COVID-19 antibody cocktail – the experimental treatment that U.S. President Donald Trump received – significantly reduced medical visits in a trial of more than 500 patients with mild-to-moderate sickness.
The company said it has shared the results with the U.S. Food and Drug Administration as part of its review of the company’s request for emergency use authorization of the treatment.
(Reporting by Michael Erman; Editing by Leslie Adler)
